open access

Vol 89, No 4 (2021)
Letter to the Editor
Submitted: 2021-01-14
Accepted: 2021-04-10
Published online: 2021-09-02
Get Citation

Potential effects of a flavonoid, hesperidin on SARS-CoV-2 disease

Mohammad Reza Khazdair1
DOI: 10.5603/ARM.a2021.0093
·
Pubmed: 34494247
·
Adv Respir Med 2021;89(4):472-473.
Affiliations
  1. Pharmaceutical Science and Clinical Physiology, Cardiovascular Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran

open access

Vol 89, No 4 (2021)
LETTERS
Submitted: 2021-01-14
Accepted: 2021-04-10
Published online: 2021-09-02

Abstract

Not available

Abstract

Not available
Get Citation

Keywords

flavonoid; hesperidin; antiviral effect; anti-inflammatory effect; SARS-CoV-2

About this article
Title

Potential effects of a flavonoid, hesperidin on SARS-CoV-2 disease

Journal

Advances in Respiratory Medicine

Issue

Vol 89, No 4 (2021)

Article type

Letter to the Editor

Pages

472-473

Published online

2021-09-02

DOI

10.5603/ARM.a2021.0093

Pubmed

34494247

Bibliographic record

Adv Respir Med 2021;89(4):472-473.

Keywords

flavonoid
hesperidin
antiviral effect
anti-inflammatory effect
SARS-CoV-2

Authors

Mohammad Reza Khazdair

References (25)
  1. Guan WJ, Ni ZY, Hu Yu, et al. China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382(18): 1708–1720.
  2. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020; 181(2): 271–280.e8.
  3. Singhal T. A review of coronavirus disease-2019 (COVID-19). India J Pediatric. 2020; 87(4): 281–286.
  4. Cameron MJ, Bermejo-Martin JF, Danesh A, et al. Human immunopathogenesis of severe acute respiratory syndrome (SARS). Virus Res. 2008; 133(1): 13–19.
  5. Zhang H, Du F, Cao XJ, et al. Evidence-Based Medicine Chapter of China International Exchange and Promotive Association for Medical and Health Care (CPAM), Chinese Research Hospital Association (CRHA). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223): 497–506.
  6. Khazdair MR, Anaeigoudari A, Kianmehr M. Anti-Asthmatic effects of and its constituents, a review. J Pharmacopuncture. 2019; 22(3): 122–130.
  7. Kianmehr M, Khazdair MR. Possible therapeutic effects of stigma and its petal flavonoid, kaempferol, on respiratory disorders. Pharm Biol. 2020; 58(1): 1140–1149.
  8. Tapas AR, Sakarkar DM, Kakde RB. Flavonoids as nutraceuticals: A review. Tropical Journal of Pharmaceutical Research. 2008; 7(3).
  9. Khazdair MR, Alavinezhad A, Boskabady MH. Carvacrol ameliorates haematological parameters, oxidant/antioxidant biomarkers and pulmonary function tests in patients with sulphur mustard-induced lung disorders: A randomized double-blind clinical trial. J Clin Pharm Ther. 2018; 43(5): 664–674.
  10. Lin CW, Tsai FJ, Tsai CH, et al. Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds. Antiviral Res. 2005; 68(1): 36–42.
  11. Wilmsen PK, Spada DS, Salvador M. Antioxidant activity of the flavonoid hesperidin in chemical and biological systems. J Agric Food Chem. 2005; 53(12): 4757–4761.
  12. Dong W, Wei X, Zhang F, et al. A dual character of flavonoids in influenza A virus replication and spread through modulating cell-autonomous immunity by MAPK signaling pathways. Sci Rep. 2014; 4: 7237.
  13. Saha RK, Takahashi T, Suzuki T. Glucosyl hesperidin prevents influenza a virus replication in vitro by inhibition of viral sialidase. Biol Pharm Bull. 2009; 32(7): 1188–1192.
  14. Wu C, Liu Y, Yang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020; 10(5): 766–788.
  15. Singh S, Sk MdF, Sonawane A, et al. Plant-derived natural polyphenols as potential antiviral drugs against SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) inhibition: an analysis. J Biomol Struct Dyn. 2020 [Epub ahead of print]: 1–16.
  16. Fu Z, Chen Z, Xie Q, et al. Hesperidin protects against IL-1β-induced inflammation in human osteoarthritis chondrocytes. Exp Ther Med. 2018; 16(4): 3721–3727.
  17. Tsai YF, Chen YR, Chen JP, et al. Effect of hesperidin on anti-inflammation and cellular antioxidant capacity in hydrogen peroxide-stimulated human articular chondrocytes. Process Biochemistry. 2019; 85: 175–184.
  18. Abuelsaad ASA, Allam G, Al-Solumani AAA. Hesperidin inhibits inflammatory response induced by Aeromonas hydrophila infection and alters CD4+/CD8+ T cell ratio. Mediators Inflamm. 2014; 2014: 393217.
  19. Manivasagam T, Nataraj J, Tamilselvam K, et al. Antioxidant and anti-inflammatory potential of hesperidin against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced experimental Parkinson′s disease in mice. International Journal of Nutrition, Pharmacology, Neurological Diseases. 2013; 3(3): 294.
  20. Kobayashi J, Murata I. Nitric oxide inhalation as an interventional rescue therapy for COVID-19-induced acute respiratory distress syndrome. Ann Intensive Care. 2020; 10(1): 61.
  21. Hedenstierna G, Chen L, Hedenstierna M, et al. Nitric oxide dosed in short bursts at high concentrations may protect against Covid 19. Nitric Oxide. 2020; 103: 1–3.
  22. Rizza S, Muniyappa R, Iantorno M, et al. Citrus polyphenol hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial function and reducing inflammatory markers in patients with metabolic syndrome. J Clin Endocrinol Metab. 2011; 96(5): E782–E792.
  23. Maneesai P, Bunbupha S, Potue P, et al. Hesperidin prevents nitric oxide deficiency-induced cardiovascular remodeling in rats via suppressing TGF-β1 and MMPs protein expression. Nutrients. 2018; 10(10).
  24. Berlin I, Thomas D, Le Faou AL, et al. COVID-19 and smoking. Nicotine Tob Res. 2020; 22(9): 1650–1652.
  25. Froldi G, Dorigo P. Endothelial dysfunction in Coronavirus disease 2019 (COVID-19): Gender and age influences. Med Hypotheses. 2020; 144: 110015.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl